Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066430 · ClinicalTrials.gov registry record · Phase 1
Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
A Phase 1 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00066430 is a Phase 1 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 18 participants.
The verdict
NCT00066430, a Phase 1 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Infrared coagulation may be effective in preventing the development of anal cancer in patients who have anal neoplasia. PURPOSE: Pilot study to evaluate the effectiveness of infrared coagulation in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia.
Interventions
- PROCEDURE infrared photocoagulation therapy
- DEVICE Infrared Coagulator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-09 |
| Est. Completion | 2006-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066430
The ClinicalTrials.gov registry entry for NCT00066430 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which infrared photocoagulation therapy is the first listed.
NCT00066430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066430 about?
NCT00066430 is a clinical study titled "Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia". RATIONALE: Infrared coagulation may be effective in preventing the development of anal cancer in patients who have anal neoplasia. PURPOSE: Pilot study to evaluate the effectiveness of infrared coagulation in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia.
What is the current status of trial NCT00066430?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-09. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00066430?
The interventions under investigation include: infrared photocoagulation therapy (PROCEDURE), Infrared Coagulator (DEVICE).
Who is sponsoring clinical trial NCT00066430?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.